Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ROIVBullishIndustry Newsnews

High materiality9/10

Roivant's Pulmovant reports strong mosliciguat PH-ILD phase 2 data, ROIV uplift

Sep 8, 2026, 9:54 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong efficacy signals (PVR reduction, 6MWD gains) and a Phase 3 catalyst underpin upside; premarket jump confirms demand, but Phase 3 execution risk tempers it.

AI summary

What happened, with direct paths to the underlying reporting

Pulmovant disclosed topline Phase 2 results for mosliciguat in PH-ILD at ERS 2026, showing a 56.3% placebo-adjusted PVR drop at Week 16, plus meaningful gains in 6MWD and NT-proBNP. A Phase 3 PHrontier program is underway, potentially accelerating ROIV's path to approval and reshaping the stock's near-term risk/reward.

Pulmovant releases topline Phase 2 mosliciguat PH-ILD data.
PVR reduced 56.3% vs placebo at Week 16; primary endpoint achieved.
Secondary endpoints: +35.2m 6MWD; NT-proBNP -357.7 pg/mL.
Week 24 exploratory results: +52.7m 6MWD; NT-proBNP -487.1 pg/mL (75.9% decline).
Phase 3 PHrontier enrollment initiated; up to 200k Group 3 PH-ILD patients.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Roivant's Pulmovant reports strong mosliciguat PH-ILD phase 2 data, ROIV uplift

Roivant-backed Pulmovant to Present Phase 2 Mosliciguat PHocus Data at ERS 2026

FDA approves Roivant/Priovant oral therapy, signaling ROIV upside potential

Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial

Roivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trial